Head-to-head · WeighScore
Gimme Care vs Zeuss
By GLP-1 ScorecardUpdated
Score comparison
Gimme Care has the higher recorded score — 84.6/100 to 65.8/100.
Gimme Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-value both-molecule pricing ($130/$163), verified, and nationwide.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Gimme Care | Zeuss |
|---|---|---|
| WeighScore | 84.6/100 | 65.8/100 |
| Grade | B | C |
| Site position | #15 | #237 |
| Semaglutide | $130/mo | $125/mo (compounded) |
| Tirzepatide | $163/mo | $175/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #15 · B
Strengths
- $130 sema / $163 tirz
- All 50 states, LegitScript-verified
- Both molecules
What to consider
- Not the cheapest tier
- Injection-only
- Monitoring detail limited
Site position #237 · C
FDAWarning letter issued to Zeuss LLC dba Zeuss in February 2026. See the FDA warning-letter database.
Strengths
- One-time-purchase model with no subscription — genuinely rare among DTC GLP-1 providers
- Publishes the FDA compounded-medication disclaimer
- Names both 503A and 503B compounding pathways — uncommon transparency
- Bundled pricing covers provider review, meds, and cold-chain shipping with no hidden fees
- Full refund if a physician can't prescribe
What to consider
- 503A pharmacy partner not named (only generic '503A and 503B state-licensed' framing)
- LegitScript certification not mentioned
- No named medical director or physician leadership
- Full states-served list not disclosed
- FDA issued Zeuss LLC dba Zeuss a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.